Atypical antipsychotics: New drugs, new challenges

Article Type
Changed
Wed, 07/18/2018 - 14:56
Display Headline
Atypical antipsychotics: New drugs, new challenges
Article PDF
Author and Disclosure Information

Manu Mathews, MD
Department of Psychiatry and Psychology, Cleveland Clinic

David J. Muzina, MD
Vice Chair for Research and Education, Director of the Bipolar Disorders Research Unit; and Director of Adult Inpatient Services, Department of Psychiatry and Psychology, Cleveland Clinic

Address: David J. Muzina, MD, Department of Psychiatry and Psychology, P57, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail:muzinad@ccf.org

Dr. Muzina has disclosed that he has received honoraria from AstraZeneca for consulting, and from AstraZeneca, Pfizer, Eli Lilly, GlaxoSmithKline, the France Foundation, CME Inc, and The Peer Group for teaching and speaking.

Issue
Cleveland Clinic Journal of Medicine - 74(8)
Publications
Topics
Page Number
597-606
Sections
Author and Disclosure Information

Manu Mathews, MD
Department of Psychiatry and Psychology, Cleveland Clinic

David J. Muzina, MD
Vice Chair for Research and Education, Director of the Bipolar Disorders Research Unit; and Director of Adult Inpatient Services, Department of Psychiatry and Psychology, Cleveland Clinic

Address: David J. Muzina, MD, Department of Psychiatry and Psychology, P57, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail:muzinad@ccf.org

Dr. Muzina has disclosed that he has received honoraria from AstraZeneca for consulting, and from AstraZeneca, Pfizer, Eli Lilly, GlaxoSmithKline, the France Foundation, CME Inc, and The Peer Group for teaching and speaking.

Author and Disclosure Information

Manu Mathews, MD
Department of Psychiatry and Psychology, Cleveland Clinic

David J. Muzina, MD
Vice Chair for Research and Education, Director of the Bipolar Disorders Research Unit; and Director of Adult Inpatient Services, Department of Psychiatry and Psychology, Cleveland Clinic

Address: David J. Muzina, MD, Department of Psychiatry and Psychology, P57, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail:muzinad@ccf.org

Dr. Muzina has disclosed that he has received honoraria from AstraZeneca for consulting, and from AstraZeneca, Pfizer, Eli Lilly, GlaxoSmithKline, the France Foundation, CME Inc, and The Peer Group for teaching and speaking.

Article PDF
Article PDF
Issue
Cleveland Clinic Journal of Medicine - 74(8)
Issue
Cleveland Clinic Journal of Medicine - 74(8)
Page Number
597-606
Page Number
597-606
Publications
Publications
Topics
Article Type
Display Headline
Atypical antipsychotics: New drugs, new challenges
Display Headline
Atypical antipsychotics: New drugs, new challenges
Sections
PURLs Copyright

Disallow All Ads
Alternative CME
Use ProPublica
Article PDF Media